Multiple primary cancer: prostate cancer Т<sub>3</sub>N<sub>х</sub>M<sub>х</sub> and melanoma Т<sub>х</sub>N<sub>х</sub>M<sub>1</sub> in patient with end-stage of chronic kidney disease on peritoneal dialysis
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Лесовой В.Н. Результаты хирургического лечения рака простаты в Харьковском регионе / Лесовой В.Н., Хареба Г.Г., Гарагатый И.А. [и др.] // Урологія. – 2015. – Т. 19, No 2 (73). – С. 61–63.
Константинова М.М. Ингибиторы внутриклеточной передачи сигнала при меланоме: перспективы и разочарования таргетной терапии / М.М. Константинова // Современная онкология. – 2007. – No 3. – С. 46–50.
Парсункова К.А. Цитокиновый профиль на фоне вакцинотерапии у больных с диссеминированной меланомой кожи / Парсункова К.А., Михайлова И.Н., Петенко Н.Н. [и др.] // Материалы Всероссийской научно-практической конференции «Опухоли кожи и мягких тканей». – СПб, 2009. – С. 31–34.
Anaya D.A. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease / Anaya D.A., Xing Y., Feng L. [et al.] // Cancer. – 2008. – Vol. 112. – P. 2030–2037.
Ascierto P.A. Adjuvant therapy of melanoma with interferon: Lessons of the past decade / Ascierto P.A., Kirkwood J.M. // Transl. Med. – 2008. – Vol. 27. – P. 62.
Atkins M.B. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial / Atkins M.B., Lee S., Flaherty L.E. [et al.] // Proc Am Soc Clin Oncol. – 2003. – Vol. 22. – P. 708.
Atzpodien J. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy group (ACIMM) / Atzpodien J., Neuber K., Kamanabroe D. [et al.] // Br. J. Cancer. 2002. – Vol. 86. – P. 179–184.
Belli F. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings / Belli F., Testori A., Revoltini L. [et al.] // J. Clin. Oncol. – 2002. – Vol. 20. – P. 4169–4180.
Carson W.E. A Phase 2 trial of a recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma / Carson W.E., Biber J., Shah N. [et al.] // Proc. Am. Soc. Clin. Oncol. – 2003. – Vol. 22. – P. 715. Abst. 2873.
Crosby T. Systemic treatments for metastatic cutaneous melanoma / Crosby T., Fish R., Coles B. [et al.] // Cochrane Database Syst. Rev. CD001215, 2000.
Davies H. Mutations of the BRAF gene in human cancer / Davies H., Bignell G.R., Cox C. [et al.] // Nature. 2002. – Vol. 417. – P. 949–954.
Del Vecchio M. Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts) / Del Vecchio M., Bajetta E., Vitali M. [et al.] // Proc. Am. Soc. Clin. Oncol. –2003. – Vol. 22. – P. 709.
Di Pucchio T. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp 100 peptides plus IFN-a results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors / Di Pucchio T., Pilla L., Capone I. [et al.] // Cancer. Res. – 2006. – Vol. 66. – P. 4943–4951.
Dummer R. Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow&up / Dummer R., Hauschild A., Pentheroudakis G. // Ann. Oncol. – 2009. – Vol. 20. – P. 129 –131.
Eggermont A.M. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage Iib/III melanoma (EORTC 18952): randomised controlled trial / Eggermont A.M., Suciu S., MacKie R. [et al.] // Lancet. – 2005. – Vol. 366. – P. 1189–1196.
Eggermont A.M. Randomized trials in melanoma: An update / Eggermont A.M. // Surg. Oncol. Clin. N. Am. – 2006. – Vol. 15. – P. 439–451.
Faries M.B. Therapeutic vaccines for melanoma: current status / Faries M.B., Morton D.L. // Bio Drags. – 2005. – Vol. 19 (4). – P. 247–460.
Flaherty K.T. New molecular targets in melanoma / Flaherty K.T. // Curr. Opin. Oncol. – 2004. – Vol. 16. – P. 150–154.
Garbe C. Adjuvant low-dose interferon alpha-2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis / Garbe C., Radny P., Linse R. [et al.] // Ann. Oncol. – 2008. – Vol. 19. – P. 1195–1201.
Gollob J.A. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction Pathway / Gollob J.A., Wilhelm S., Carter C. [et al.] // Semin. Oncol. – 2006. – Vol. 33. – P. 392–06.
Hsueh E.C. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine / Hsueh E.C., Essner R., Foshag LJ. [et al.] // J. Clin. Oncol. – 2002. – Vol. 20. – No 23. – P. 4549–554.
Korman A. Tumor immunotherapy: pre&clinical and clinical activity of antiCTLA4 antibodies / Korman A., Yellin M., Keler T. // Curr. Opin. Invest. Drugs. – 2005. – Vol. 6. – P. 582–591.
Urkhard F.C. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection / Urkhard F.C., Bader P., Schneider E. [et al.] // Eur Urol –2002. – Vol. 42(2). – P. 84–90.
Chan T.Y. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? / Chan T.Y., Chan D.Y., Lecksell K. [et al.] // J Urol. – 2001. – Vol. 166. – P. 2181.
Coakley F.V. Magnetic resonance imaging and spectroscopic imaging of prostate cancer / Coakley FV, Qayyum A, Kurhanewicz J. // J Urol . – 2003. – Vol. 170 (suppl). – P. 69–76.
Djavan B. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens / Djavan B, Kadesky K, Klopukh B [et al.] // Eur Urol. – 1998. – Vol. 33 (3). – P. 261–70.
Djavan B. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study / Djavan B, Mazal P, Zlotta A. [et al.] / Prostate. – 2001. – Vol. 47(2). – P. 111–7.
Gore J.L. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer / Gore J.L., Shariat S.F., Miles B.J [et al.] / J Urol. – 2001. – Vol. 165. – P. 1554.
Harisinghani M.G. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer / Harisinghani M.G., Barentsz J., Hahn P.F. [et al.] // N Engl J Med. – 2003. – Vol. 348 (25). – Р. 2491–9.
Horiguchi A. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer / Horiguchi A., Nakashima J, Horiguchi Y. [et al.] // Prostate. – 2003. – Vol. 56. – P. 23–29.
Presti J. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study / Presti J.C., O’Dowd G.J., Miller M.C. [et al.] // J Urol. – 2003. – Vol. 169. – P. 125.
Purohit R. S. Imaging clinically localized prostate cancer / Purohit R S, Shinohara K, Meng MV, Carroll PR. // Urol Clin North Am. – 2003. – Vol. 30. – P. 279–293.